Breast cancer remains a leading cause of cancer-related mortality in women, reflecting
profound disease heterogeneity, metastasis, and therapeutic resistance. Over the last …

Recent advances in cancer immunotherapy—ranging from immune-checkpoint blockade
therapy to adoptive cellular therapy and vaccines—have revolutionized cancer treatment …

CD8+ T cells are end effectors of cancer immunity. Most forms of effective cancer
immunotherapy involve CD8+ T cell effector function. Here, we review the current …

Immune checkpoint inhibitor (ICI) therapy can induce complete responses in mismatch
repair-deficient and microsatellite instability-high (d-MMR/MSI-H) colorectal cancers (CRCs) …

The metabolic stress occurring in the tumor microenvironment (TME) hampers T cell anti-
tumor immunity by disturbing T cell metabolic and epigenetic programs. Recent studies are …

The NOTCH gene was identified approximately 110 years ago. Classical studies have
revealed that NOTCH signaling is an evolutionarily conserved pathway. NOTCH receptors …

BACKGROUND Tertiary lymphoid structures (TLSs) are organized aggregates of immune
cells that form postnatally in nonlymphoid tissues. TLSs are not found under physiological …

Tumour heterogeneity and a long-standing paucity of effective therapies other than
chemotherapy have contributed to triple-negative breast cancer (TNBC) being the subtype …

Breast cancers are complex cellular ecosystems where heterotypic interactions play central
roles in disease progression and response to therapy. However, our knowledge of their …